Cybin Inc. (CYBN)
USD 6.5
(-1.81%)
USD 6.5
(-1.81%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -78.08 Million CAD | -95.02% |
| 2022 | -40.03 Million CAD | 43.94% |
| 2021 | -71.42 Million CAD | -121.68% |
| 2020 | -32.22 Million CAD | -1557.41% |
| 2019 | -1.94 Million CAD | -1833.87% |
| 2018 | -100.52 Thousand CAD | 0.0% |
| 2016 | -127.21 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -14.82 Million CAD | 30.55% |
| 2023 Q3 | -30.33 Million CAD | -155.09% |
| 2023 FY | -78.08 Million CAD | -95.02% |
| 2023 Q4 | -21.34 Million CAD | 29.62% |
| 2023 Q2 | -11.89 Million CAD | 3.92% |
| 2023 Q1 | -12.37 Million CAD | 9.8% |
| 2022 Q4 | -13.72 Million CAD | -27.72% |
| 2022 Q3 | -10.74 Million CAD | -7.71% |
| 2022 Q1 | -13.05 Million CAD | 27.86% |
| 2022 Q2 | -9.97 Million CAD | 23.61% |
| 2022 FY | -40.03 Million CAD | 43.94% |
| 2021 Q2 | -17.6 Million CAD | -19.64% |
| 2021 Q3 | -17.21 Million CAD | 2.25% |
| 2021 Q1 | -14.71 Million CAD | -6.81% |
| 2021 FY | -71.42 Million CAD | -121.68% |
| 2021 Q4 | -18.09 Million CAD | -5.15% |
| 2020 FY | -32.22 Million CAD | -1557.41% |
| 2020 Q3 | -11.41 Million CAD | -23252.6% |
| 2020 Q4 | -13.77 Million CAD | -20.66% |
| 2020 Q2 | -48.89 Thousand CAD | 98.88% |
| 2020 Q1 | -4.36 Million CAD | 0.0% |
| 2019 Q3 | -236.55 Thousand CAD | 0.0% |
| 2019 FY | -1.94 Million CAD | -1833.87% |
| 2018 FY | -100.52 Thousand CAD | 0.0% |
| 2016 FY | -127.21 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | -169.595% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | -13.086% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | -59.941% |
| Azitra, Inc. | -11.28 Million USD | -591.967% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -922.793% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -957.881% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | -167.251% |
| CEL-SCI Corporation | -32.36 Million USD | -141.242% |
| iBio, Inc. | -24.9 Million USD | -213.486% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | -263.399% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -294.884% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | -240.337% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -709.959% |
| NanoViricides, Inc. | -8.29 Million USD | -841.387% |
| Oragenics, Inc. | -20.65 Million USD | -278.006% |
| BiomX Inc. | -26.16 Million USD | -198.368% |
| BiomX Inc. | -26.16 Million USD | -198.368% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 1039.365% |
| Palatin Technologies, Inc. | -29.73 Million USD | -162.576% |
| Scorpius Holdings, Inc. | -45.21 Million USD | -72.678% |
| Theriva Biologics, Inc. | -18.34 Million USD | -325.527% |